Talking about earnings for the fourth quarter of 2015-16, Dinesh Dua, CEO and director of Nectar Lifesciences, says FY17 will be an important year for the company. Nectar Lifesciences awaits approval of drugs in the US which will be a big growth trigger ahead, he adds.